ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Role of autoreactivity in pathogenesis of chronic graft versus host disease

Active
Institution
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA
Principal investigator
Defu Zeng
Funding
$879K
Duration
2024–2028
Open portfolio

Moonbase score

Still being scored

Abstract

Allogeneic hematopoietic cell transplantation (Allo-HCT) is a curative therapy for patients with hematological malignancies (i.e. leukemia and lymphoma), through graft versus leukemia/lymphoma (GVL) effect mediated by alloreactive donor T cells. However, graft-versus-host disease (GVHD) caused by the same alloreactive T cells remains a major obstacle. Chronic GVHD (cGVHD), a systemic autoimmune-like syndrome, remains a major cause of morbidity and mortality in long-term survivors of Allo-HCT. During the past decade, we have used murine and humanized murine models of cGVHD and biospecimens from cGVHD patients to demonstrate that CD4+ T cells and B cells and their interactions in GVHD target tissues such as the liver, lung and skin play a critical role in the pathogenesis and persistence of the disease. The premise of this new proposal is that deeper mechanistic understanding of the interactions between non-circulating tissue- resident CD4+ memory T (Trm) and tissue-resident B (Brm) cells in GVHD target tissues will identify new therapeutic targets for prevention or treatment of cGVHD. In Aim 1, we will determine whether CD4+ Trm cells initiate formation of tertiary lymphoid structures (TLS) in GVHD target tissues, in which Ly108+ stem cell-like progenitors maintain the pool of Trm and Brm to perpetuate cGVHD pathogenesis. We will also develop novel cell-penetrating PS-Cas9-gRNA to target STAT3 in donor T cells to prevent development of pathogenic CD4+ Trm and cGVHD while preserving GVL activity, because our recent studies indicate that STAT3 is required for Trm development. In Aim 2, we will determine whether B cell helper PD-1hiPSGL1loCD4+ Trh cells interact with T-bet+ Brm cells to produce autoantibodies that augment systemic tissue damage. In Aim 3, we will determine whether non-B cell helper PSGL1hiCD4+ Trm cells interact with dendritic cells, macrophages, and fibroblasts in cGVHD target tissues to mediate damage and fibrosis in an IL-33/ST2 pathway-dependent manner. These studies have high biological and translational significance and may lead to a paradigm shift in our understanding of cGVHD pathogenesis and to development of novel approaches for preventing and treating cGVHD.

LOADING MOONBASE SCORE

NATIONAL HEART, LUNG, AND BLOOD INSTITUTER01Transplantation, Tolerance, and Tumor Immunology Study Section[TTT]helpercgvhdremains majorcells interactgvhdtrm cellstrmalloreactive

Questions for BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.